Rubicon Research Limited
Indian Pharmaceutical Exporter ยท Cardiovascular Specialist ยท $11.1M Total Trade ยท DGFT Verified
Rubicon Research Limited is an Indian pharmaceutical exporter with a total trade value of $11.1M across 8 products in 4 therapeutic categories. Based on 357 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metoprolol ($4.4M), Carvedilol ($2.0M), Clonazepam ($1.8M).
Rubicon Research Limited โ Export Portfolio & Destination Treemap

Who is Rubicon Research Limited? โ Company Overview & Market Position
Rubicon Research Limited, established on May 6, 1999, is a publicly listed pharmaceutical company headquartered in Thane, Maharashtra, India. The company specializes in the development, manufacturing, and commercialization of generic and specialty pharmaceutical formulations. Its product portfolio spans various therapeutic categories, including cardiovascular, central nervous system (CNS), and antimalarial treatments. Rubicon Research Limited is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 544578 and on the National Stock Exchange of India (NSE) under the ticker symbol RUBICON.
The company's authorized capital is โน23.90 crore, with a paid-up capital of โน16.48 crore. As of the latest available data, Rubicon Research Limited employs approximately 827 professionals. The corporate office is located at MedOne House, B-75, Road No. 33, Wagle Estate, Thane (West), Maharashtra 400604, India.